Capricor Therapeutics (CAPR) Total Liabilities (2010 - 2026)

Capricor Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $47.6 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 82.16% year-over-year to $47.6 million; the TTM figure through Mar 2026 stood at $47.6 million (up 82.16% YoY), while the FY2025 annual figure was $50.2 million, up 100.48% from the prior year.
• Total Liabilities for Q1 2026 stood at $47.6 million, down from $50.2 million in the prior quarter.
• The five-year high for Total Liabilities was $50.2 million in Q4 2025, with the low at $24.7 million in Q3 2024.
• The 5-year median for Total Liabilities is $38.5 million (2022), against an average of $36.8 million.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities surged 504.94% in 2022, then tumbled 38.14% in 2024.
• Capricor Therapeutics' Total Liabilities stood at $38.3 million in 2022, then fell by 5.68% to $36.1 million in 2023, then tumbled by 30.76% to $25.0 million in 2024, then surged by 100.48% to $50.2 million in 2025, then slipped by 5.14% to $47.6 million in 2026.
• Business Quant data shows CAPR's Total Liabilities at $47.6 million in Q1 2026, $50.2 million in Q4 2025, and $42.6 million in Q3 2025.